SCHEDULE 13G: Perceptive Advisors and Affiliates Disclose 5.1% Stake in Biodesix, Inc.

Perceptive Advisors LLC, along with its affiliates and Joseph Edelman, has disclosed a collective beneficial ownership of 5.1% in Biodesix, Inc., totaling 7,673,880 shares, including exercisable warrants.

Summary

• Perceptive Advisors LLC, Joseph Edelman, Perceptive Credit Advisors LLC, PCOF EQ AIV IV, LP (Opportunity Fund), and Perceptive Credit Holdings IV, LP (Credit Fund) have filed a Schedule 13G, reporting their beneficial ownership in Biodesix, Inc.
• The aggregate beneficial ownership across these reporting persons is 7,673,880 shares of Biodesix, Inc. Common Stock, representing 5.1% of the class.
• This ownership percentage is calculated based on 146,563,031 shares of Common Stock outstanding as of May 7, 2025, as reported in Biodesix's Form 10-Q filed on May 13, 2025, and includes the effect of exercisable warrants.
• The Credit Fund directly holds 1,036,560 shares of Common Stock and 5,500,000 warrants to purchase shares of Common Stock.
• Of the warrants, 5,000,000 are exercisable at $1.0648 per share, and 500,000 are exercisable at $1.6254 per share.
• The Opportunity Fund directly holds 1,137,320 shares of Common Stock.
• The warrants held by the Credit Fund and Opportunity Fund can be fully exercised without exceeding the 9.99% beneficial ownership threshold.
• The securities were not acquired for the purpose of changing or influencing the control of Biodesix, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant institutional investment by a reputable firm, Perceptive Advisors, which can be viewed as a vote of confidence in Biodesix, Inc. However, it is a factual ownership disclosure rather than a performance report.

Positives

• The disclosure of a significant 5.1% stake by institutional investors like Perceptive Advisors and its affiliates may signal confidence in Biodesix, Inc.'s long-term prospects.
• The ability to exercise all warrants without exceeding the 9.99% beneficial ownership limit provides flexibility for the reporting persons.

Negatives

• NA

Risks

• The value of the investment is subject to the market performance of Biodesix, Inc.'s common stock.
• The exercise of warrants could lead to dilution for existing shareholders, although this filing indicates the warrants are already accounted for in the reported percentage.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a specialized healthcare and life sciences investment firm, Perceptive Advisors, in Biodesix, Inc., a company operating in the biotechnology and diagnostics sector. Such institutional investments can be a signal of perceived value or growth potential within the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence investor sentiment and potentially the stock price, signaling institutional confidence.
• Company Management: Awareness of a significant institutional shareholder may influence strategic decisions and corporate governance considerations.

Next Steps

• The reporting persons may continue to monitor their investment in Biodesix, Inc. and may adjust their holdings based on market conditions or company performance.
• Biodesix, Inc. will continue its operations and financial reporting as per SEC requirements.

Key Dates

Keywords

Biodesix Inc., Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, SEC Filing, Healthcare, Biotechnology